Research Papers:

LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway

Jie Ji, Junwei Tang, Lei Deng, Yu Xie, Runqiu Jiang, Guoqiang Li and Beicheng Sun _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:42813-42824. https://doi.org/10.18632/oncotarget.5970

Metrics: PDF 3157 views  |   HTML 3681 views  |   ?  


Jie Ji1,*, Junwei Tang1,*, Lei Deng1,*, Yu Xie1, Runqiu Jiang1, Guoqiang Li1, Beicheng Sun1

1Liver Transplantation Center of the First Affiliated Hospital and Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu Province, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Beicheng Sun, e-mail: [email protected]

Keywords: lncRNA, HCC, EpCAM, mTOR, prognosis

Received: April 27, 2015     Accepted: October 16, 2015     Published: October 26, 2015


Hepatocellular carcinoma (HCC) is well known as the sixth most common malignant tumor and the third leading cause of cancer-related deaths globally. LINC00152 was documented as an important long non-coding RNA (lncRNA) involved in the pathogenesis of gastric cancer; however, the detailed mechanism of action of LINC00152 remains unknown. Here, based on the increased level of LINC00152 in HCC tissues, we found that LINC00152 could promote cell proliferation in vitro and tumor growth in vivo. Furthermore, microarray-based analysis indicated that LINC00152 could activate the mechanistic target of rapamycin(mTOR) pathway by binding to the promoter of EpCAM through a cis-regulation, as confirmed by Gal4-λN/BoxB reporter system. Thus, LINC00152 might be involved in the oncogenesis of HCC by activating the mTOR signaling pathway and might be a novel index for clinical diagnosis in the future.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5970